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Myasthenia gravis (MG) with onset below 50 years, thymic hyperplasia and acetylcholine
receptor (AChR) antibodies is more common in females than in males. For a relatively
large group of MG patients, pregnancy represents therefore an important question.
The muscle weakness, the circulating autoantibodies, the hyperplastic thymus, the
MG drug treatment, and any autoimmune comorbidity may all influence both mother
and child health during pregnancy and also during breastfeeding in the postpartum
period. Mother’s MG remains stable in most patients during pregnancy. Pyridostigmine,
prednisolone, and azathioprine are regarded as safe during pregnancy. Mycophenolate,
methotrexate and cyclophosphamide are teratogenic and should not be used by women
with the potential to become pregnant. Rituximab should not be given during the last
few months before conception and not during pregnancy. Intravenous immunoglobulin
and plasma exchange can be used for exacerbations or when need for intensified
therapy. Pregnancies in MG women are usually without complications. Their fertility is
near normal. Vaginal delivery is recommended. MG patients have an increased rate of
Cesarean section, partly due to their muscle weakness and to avoid exhaustion, partly
as a precaution that is often unnecessary. Around 10% of the newborn develop neonatal
myasthenia during the first few days after birth. This is transient and usually mild with
some sucking and swallowing difficulties. In rare cases, transplacental transfer of AChR
antibodies leads to permanent muscle weakness in the child, and arthrogryposis with
joint contractures. Repeated spontaneous abortions have been described due to AChR
antibodies. MG women should always give birth at hospitals with experience in newborn
intensive care. MG does not represent a reason for not having children, and the patients
should be supported in their wish of becoming pregnant.
Keywords: myasthenia gravis, autoimmunity, autoantibodies, pregnancy, neonatal myasthenia, arthrogryposis,
breastfeeding, teratogenicity
INTRODUCTION
Myasthenia gravis (MG) is an autoimmune disorder where well-defined muscle antibodies bind
to the post-synaptic membrane at the neuromuscular junction (1). These antibodies induce the
muscular weakness typical for MG. In most patients, the antibodies bind to acetylcholine receptors
(AChR), but alternative targets are muscle-specific tyrosine kinase (MuSK) and lipoprotein-related
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peptide 4 (LRP4) (2). Antibody binding leads to destruction and
reduced receptor function through cross-linking of membrane
molecules, complement activation, and blockade of ligand-
binding epitopes. AChR antibody binding to the cell membrane
leads in addition to a cascade of intracellular events that
influences muscle cell function. AChR and MuSK antibodies are
highly specific for MG, as they do not occur without muscle
weakness and in the healthy population. MG severity is not
linked to autoantibody concentration, illustrating the variation
and complexity in the antigen-antibody interaction as well as the
individual variation in the consequences of this interaction.
Most females in reproductive age with MG have an enlarged
and hyperplastic thymus with widespread germinal follicles (3). A
thymoma is present in 10% of all MG patients but is less common
among young females with the disease. The thymus pathology
induces the production of AChR antibodies in lymphoid tissue
widespread in the body. The trigger for thymic hyperplasia is
not known, but virus infection has been suggested, in genetically
predisposed individuals and perhaps at an especially vulnerable
time point. Thymectomy early in the disease improves MG in
females in reproductive age (4). Thymic hyperplasia does not
occur in other autoimmune disorders, and the therapeutic effect
of thymectomy is specific for MG with AChR antibodies.
Untreated MG is a severe disease with 50% mortality after ten
years. With modern treatment, no patients should die from their
MG. Therapy combines symptomatic and immunosuppressive
drugs, thymectomy, and supportive therapy such as physical
training, vigorous treatment of infections, respiratory support in
the rare occasions it becomes necessary, and optimal treatment of
comorbidities. Most patients do well and have modest, minimal
or no muscle weakness. However, 10–20 % have a disease that is
relatively resistant to standard therapies.
MG prevalence in the general population is 150–250
individuals per million, and with an annual incidence of 8–10
individuals per million (5). As both prevalence and incidence
increase with increasing age, these figures are somewhat lower
among females in reproductive age. MG prevalence in European
females below age 50 years is thought to be 120 per million, and
annual incidence 5–10 per million (5). MG with onset below
age 50 years and AChR antibodies is 2–3 times more common
in females than in males, and women have an incidence peak
at age 30 years. In China and other Far East countries, juvenile
MG is much more common than in Western populations, and
MG with debut in childhood represents a third incidence peak
(6). MuSK MG is more common in older age groups. However,
in a multinational study from mainly Western countries, 70%
had MuSK MG debut before age 40 years, and the females had
a mean debut age of 31 years (7). MuSK MG is twice as common
in females as in males. The relative number of MG patients
in different age groups depends for a large part on population
demographics. In younger populations in Africa, South-America
and Africa, pregnancy and childbirth is relevant for a much larger
proportion of MG patients than in Europe.
Mother’s age when giving birth has increased markedly during
the last decades, especially in Western countries. In Norway, the
mean age was in 2018 31 years, up from 29 years ten years ago.
Similarly, mean age at first childbirth has increased from 23.5
years in 1975 to 25.5 years in 1990, and to 29.5 years in 2018
(www.ssb.no/fodte). This increased age at childbirth means that a
higher proportion of MG females will experience childbirth after
manifest disease.
For females in reproductive age with MG, one of their major
concerns is potential consequences for fertility, pregnancy, giving
birth, and lactation (8). Any risks for the child as well as for
themselves are of the highest importance. Furthermore, they
would like to know about any geneticMG predisposition for their
children. Precise information about these factors to the patients
and to all caretakers during the pregnancy and in the perinatal
period should have a supportive and encouraging effect, and
also improve the outcome. MG females often have exaggerated
worries and postpone or avoid pregnancy unnecessarily.
MOTHER’S MG
The much higher MG frequency in females than in males
during the whole reproductive period strongly indicates that
sex hormones play a role in MG pathogenesis. Experimental
studies support a role of estrogens and progesterone (9). Thus,
both pregnancy, puerperium and lactation would be expected
to have the capacity to influence the course of MG. There
are several case reports of MG debut during pregnancy, both
for AChR- and MuSK antibody-mediated disease. Relative risk
of MG onset before, during, and shortly after pregnancy has
been calculated in a population-based cohort study combining
data from Norway and The Netherlands. 246 women with
MG onset at age 15–45 years were included (10). The authors
found that the relative risk for onset during pregnancy was
not increased. In contrast, this risk increased markedly, with
a factor of around five, during the first 6 months postpartum.
During the next 6 months, the relative risk normalized. The risk
was highest after the first childbirth. Similar results have been
reported for other autoimmune disorders such as thyroiditis and
rheumatoid arthritis (11). Both hormonal, immunological, and
stress mechanisms have been put forward as explanations forMG
debut shortly after childbirth.
Established and stable MG can be influenced by pregnancy.
Pregnancy is associated with changes in immune and endocrine
signaling that can influence autoimmune diseases in general (12).
In a series of 69MG pregnancies, 30% had an exacerbation,
45% had no change, and 25% improved (13). In several similar
case series, each with relatively few patients, a deterioration
occurred in 35–45% of MG pregnancies (14–18). The rates for
exacerbation tended to be higher than for improvement, whereas
a substantial proportion remained unchanged. The exacerbations
were generally mild to moderate, and myasthenic crisis during
pregnancy is rare. Exacerbations occurred more commonly
during the first 6 months postpartum than in the pregnancy (17).
There were no specific characteristics for the MG patients with
exacerbations during pregnancy. Neither previous thymectomy,
AChR antibody concentration, nor years since MG debut seemed
to be determinants. MG with more severe symptoms before
pregnancy usually remained more severe also during this period.
More surprisingly, the outcome regarding mother’s MG during
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previous pregnancies did not predict the development next time.
This supports the conclusion that pregnancy by itself represents
no major risk factor for MG and that non-pregnancy factors are
more important both for short-term and long-termMGoutcome.
In the postpartum period, however, there is an increased risk for
both debut of MG and MG deterioration. Among 27 pregnancies
either before or duringMGwithMuSK antibodies, the pregnancy
and puerperium did not precipitate or influence mother’s muscle
weakness (19).
Symptomatic treatment with the acetylcholine esterase
inhibitor pyridostigmine is regarded safe and should be
continued during pregnancy (20, 21). The drug does not
cross placenta in significant amounts. Optimal pyridostigmine
treatment is important for most MG women’s general health
during pregnancy. Some of the reported MG exacerbations
during pregnancy is probably due to dose reduction or
withdrawal of effective treatments due to fear for harmful effects
for the child. Intravenous injections of acetylcholine esterase
inhibitor should be avoided during pregnancy as this can lead to
increased uterine contractions.
Mycophenolate mofetil, methotrexate and cyclophosphamide
are teratogenic immunosuppressive drugs that should
not be given to pregnant women (20–22). These drugs
should therefore be avoided for all women in reproductive
age, at least if there is any chance for pregnancy. Both
prednisone/prednisolone and azathioprine are regarded as
safe during pregnancy. These are the most common first-
line immunosuppressive drug therapies for MG. Rituximab
is increasingly used for moderate and severe MG. This
is a monoclonal antibody that crosses the placenta. The
drug will bind to B-lymphocytes in the developing child
and should therefore be avoided the last months before as
well as during pregnancy. Newborns of mothers treated
with rituximab have transient B-cell depletion (23). This
will normalize after 6 months, but it is not known if such
children will experience any long-term immunoregulatory
complications. Teratogenicity is not a risk for rituximab.
Intravenous immunoglobulin and plasma exchange represent
safe treatments during pregnancy. Due to convenience and
general safety, intravenous immunoglobulin is often the
preferred treatment for an MG exacerbation during pregnancy,
and for a stable severe or moderately severe MG condition as
well. Thymectomy as MG treatment should not be undertaken
during pregnancy.
PREGNANCY IN MG
MG is not expected to influence fertility. There is an overlap
with other autoimmune disorders, and with some that may be
associated with female infertility. This has been reported for
thyroid disease with reduced thyroid function, SLE, and anti-
phospholipid syndrome (24). Autoantibodies per se do not seem
to be associated with infertility. The commonly used drugs inMG
should not reduce fertility. Females with MG tend to have fewer
children than healthy women, but this can be explained by other
reasons than reduced fertility (8).
Pregnancy is for the large majority of MG females
uncomplicated, and MG women should be supported when
they wish to have children. However, in a cross-sectional study
from Germany, one half of the MG females reported that they
had abstained from having a child or further children due to
their disease (8). The most common cause was fear of adverse
drug effects on the child. The knowledge level was generally
low among the MG women. Most pregnancy complications
occur with a similar frequency with and without MG, including
preeclampsia and eclampsia. However, preterm rupture of
amniotic membranes shows an increased frequency, and
especially in those with MG deterioration during the pregnancy
(15, 25, 26).
Spontaneous abortion may occur with a slightly increased
frequency in MG. The exact frequency of miscarriages is difficult
to know due to small case series reported, and in addition the
possibility of selection bias in the reports. Seven miscarriages
among 36 pregnancies were found in a French study (18), 10
among 64 in a similar Italian study (14), 4 among 27 in a Turkish
cohort (15), and 5 among 35 in Brazil (16). This indicates a rate
of around 15%. This is similar to the miscarriage rate in the
general population of 10–20% among women who know they are
pregnant. A recent study reported a 24% pregnancy loss rate in
females with a spectrum ofmedical disorders on azathioprine and
a 50% risk on mycophenolate mofetil (27).
Folic acid supplement is recommended for MG women in the
same way as for other women. The standard recommendation is
400mg daily before and during pregnancy to reduce the risk of
birth defects (28).
GIVING BIRTH IN MG
MG women should be advised to give birth by vaginal delivery,
similar to women without MG. However, all case series reports
show an increased frequency of Cesarean section. In a national
and registry-based Norwegian cohort, 17% of MG females had
Cesarean section compared to 8.6% in the total population
(25). Both elective and emergency sections were increased.
Interestingly, the Cesarean section rate was 15% also in females
that had no MG diagnosis when giving birth but had developed
overt MG at a later delivery (29). In other MG patient series,
the Cesarean section rate is much higher, but with similarly
increased rates for the general population. In Taiwan, 45% of MG
women had Cesarean section, compared to 37.4% of the general
population (30). More than 50 countries in the world have
Cesarean section rates above 27% for the total population (31).
The British guidelines state that Cesarean section in MG should
be performed only for obstetric indications (20). These include
prolonged labor with an exhausted mother. Interventions with
vacuum or forceps are slightly more common in MG, 9% in MG
vs. 6% in the general population in the Norwegian cohort (25).
MG women should continue with their standard drug
treatment during the last part of pregnancy and during labor.
Epidural analgesia is preferable to general anesthesia whenever
possible (20), and is performed in the large majority of those
with Cesarean section (16). Most anesthetic drugs are, however,
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safe in MG. Giving birth at a hospital with experience in
neonatal intensive care and with access to a multidisciplinary
team involvement by obstetrician, anesthetist, neonatologist, and
neurologist is strongly recommended. A protocol with epidural
labor analgesia and early use of vacuum extraction for maternal
MG has been suggested (32).
NEONATAL MYASTHENIA
Around 10% of the babies of mothers with MG have a transient
muscle weakness. This is due to antibodies against AChR
or MuSK that are transported from the mother’s circulation,
across placenta, and to the fetus (21, 33). In the baby, these
antibodies may bind to their respective antigens and induce
muscle weakness. If present, the weakness will nearly always
appear during the first 24 h after birth. Asmother’s IgG antibodies
are broken down in the baby and gradually disappear, the muscle
weakness improves, and normal function is achieved (14). The
weakness usually lasts for up to 4 weeks but is most pronounced
during the first week.
Typical symptoms are some general hypotonia and poor
sucking due to reduced muscle strength. Dysphagia and a weak
cry are other possible manifestations. Insufficient respiration,
aspiration and pneumonia are rare complications, but make
neonatal ward observation necessary for these babies.
In a Norwegian nationwide cohort without selection bias,
5 out of 125MG babies had definite neonatal myasthenia and
another 10 were transferred to a neonatal ward (26). Various
case series have reported transient neonatal myasthenia in 4/31,
6/27, 2/30, 1/36, and 5/55 mothers with MG (14–18). This sums
up to a frequency of around 10%. The different results can
probably best be explained by variation in diagnostic sensitivity
for neonatal myasthenia.
Neonatal myasthenia can occur in babies of MG mothers
with both AChR and MuSK antibodies, but also in patients
without detectable muscle antibodies (34). A large proportion
of MG patients where no antibodies can be detected by routine
assays, still have such antibodies but with low affinity or in
low concentration (35). There is no direct correlation between
severity of mother’s MG and risk for neonatal myasthenia, nor
is there a correlation to antibody concentration in the mother.
Transport of IgG across placenta shows individual variation
and depends also on properties of the antibodies such as IgG
subclass. The serum IgG concentrations in mother and child
at delivery are similar, illustrating the efficient transplacental
transport during the end of the pregnancy. Epitope specificity
of the AChR or MuSK antibody is an important determinant
for myasthenic disease, and the configuration and antigenicity
of AChR differ between mother and her newborn child (26).
Neonatal myasthenia in a previous child increases the risk for the
condition in the next ones (36). Previous thymectomy seems to
reduce the risk for neonatal myasthenia (37).
Most cases of neonatal myasthenia are so mild that no
treatment is needed. Very low doses of the acetylcholine
esterase drugs pyridostigmine and neostigmine will improve
muscle strength (20). Supportive treatment, for example
help with breastfeeding, is important. Treatment with
intravenous immunoglobulin or plasma exchange is only very
rarely needed.
PERSISTENT SEQUELA IN THE CHILD
The great majority of children of MG mothers are healthy and
with no persistent muscle weakness or motor disabilities. This
is true also for those with transient neonatal myasthenia. IgG
transport across placenta does not appear until pregnancy week
13, after the organ-forming period. In pregnancy week 17–22, the
IgG concentration in the child is still only 5–10% of that in the
mother (38, 39).
Arthrogryposis with skeletal abnormalities and joint
contractures is a rare condition but has increased frequency
in children of MG mothers (40). Five out of 127 such
children (3.9%) in the Norwegian national cohort had such
malformations (25). No cases of congenital malformations
have been reported in other case series with 26 and 30
children (16, 17). MG in mother does not seem to be a
major causative risk factor for arthrogryposis (41). As for
neonatal myasthenia, a previous child with arthrogryposis
represents a definite risk factor in the next pregnancy (26). Such
women should be treated with intravenous immunoglobulin
or plasma exchange in all later pregnancies. The cause of
arthrogryposis is restricted fetal movements in utero. When
mother has MG the movement restriction is due to mother’s
IgG antibodies binding to fetal type AChR with gamma
subunits. Arthrogryposis can occur in babies of mothers also
with only mild MG. Fetal movements should be monitored
as accurately as possible (40) in all women with MG, as there
is effective treatment to inhibit arthrogryposis to develop in
MG mothers.
In rare, single cases, a permanent muscle weakness has been
reported in children of MG mothers (42, 43). This weakness
can be generalized or isolated, for example as a facial paresis.
This is not a fluctuating condition due to persistent antibodies,
but rather a permanent change in the postsynaptic membrane
induced by mother’s AChR antibodies during fetal life. Such a
fetal AChR inactivation syndrome has been reported in eight
children from four families (42).
BREASTFEEDING
Breastfeeding should be encouraged for MG mothers (20, 21).
This is true both for those with AChR and MuSK antibodies.
Maternal lgG levels in milk comprise only 2% of that in serum.
In humans, breast milk does not represent a source for immunity
transfer from mother to child. Breastfeeding is recommended
also for babies with neonatal myasthenia. Being breastfed has
many advantages, including a reduced risk for autoimmune
disease later in life (44).
Breastfeeding is not known to influence mother’s MG. There
is an increased risk for worsening of MG in the puerperium,
similar to other autoimmune disorders. Boldingh et al. found that
debut of MG in the postpartum period was more common in The
Frontiers in Neurology | www.frontiersin.org 4 June 2020 | Volume 11 | Article 554
Gilhus Myasthenia, Pregnancy and the Child
Netherlands than in Norway, and they speculated that the much
higher frequency of prolonged breastfeeding in Norway might
have a protective role (10).
Breastfeeding is advised against in MG mothers with ongoing
treatment with cyclophosphamide, mycophenolate mofetil or
methotrexate (20). The reason is the teratogenic potential of these
drugs. Cyclophosphamide is excreted into breast milk. Maternal
treatment with pyridostigmine, prednisolone/prednisone, or
azathioprine represents no contraindication for breastfeeding.
Transfer of these drugs and their metabolites into breast milk is
minimal. Breastfeeding is most probably safe also for treatment
with rituximab, cyclosporine, and tacrolimus. The concentration
of rituximab in breast milk is 200 times less than in serum (45).
Intravenous immunoglobulin or plasma exchange can be used
for MG exacerbations in the postpartum period irrespective of
breastfeeding or not. Breastfeeding should be encouraged for
women on treatment with monoclonal antibodies, and at the
same time register outcome (46).
COMORBIDITIES
MGwomen have an increased frequency of all other autoimmune
disorders (47). Such disorders need to be taken into consideration
for women before and during pregnancy, both their clinical
manifestations and their treatment. In a minority of young
women, the MG is caused by a thymoma. Most MG-related
thymomas should not influence pregnancy, but in rare cases
either thymoma treatment or non-MG thymoma-associated
autoimmune disease may be of significance. Infections should
always be treated actively in MG patients, and with specific
considerations regarding choice of anti-infectious drugs (48).
CONCLUSION
MG women with a child wish should be supported and
encouraged. Pregnancy and childbirth have similar complication
rates as for the non-MG population. Optimal drug treatment
for MG should be continued. Vaginal delivery is recommended,
and indications for Cesarean section are obstetrical and the
same as for non-MG women. Breastfeeding is safe and should
be supported. However, there are a few important warnings.
Mycophenolate mofetil, methotrexate and cyclophosphamide
should not be given to any females that may become pregnant
as these drugs have a teratogenic potential. Rituximab should be
stopped some months before a pregnancy. MG women should
always give birth at a hospital with intensive care services for
the newborn, as 10% of the babies have transient neonatal
myasthenia. All babies by MG mothers should be observed in
hospital for at least 48 h. Correct information to all females
in reproductive age is important. Obstetrical and neurological
follow-up during pregnancy makes a difference. Many MG
women have exaggerated worries and practice unnecessary
limitations or restrictions regarding pregnancy.
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